Patent intelligence · US
US 2024166750
GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
Patent details — US 2024166750
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 23, 2024
- Expiration
- May 18, 2044
- Applicant
- ABLYNX NV [BE]
- CPC classes
- A61K 39/ 00 A I
Quick answer
US 2024166750 (GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION) is held by ABLYNX NV [BE]. Status: granted. Granted May 23, 2024. Expires May 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ABLYNX NV [BE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 39/ 00 A I
More from ABLYNX NV [BE]
Related pharmaceutical patents in our USPTO index.
-
WO 2026078159
AGENTS D'ACTIVATION DE CELLULES IMMUNITAIRES ET PROCÉDÉS LES COMPRENANT
granted -
WO 2026030375
NANOPARTICULES LIPIDIQUES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
granted -
WO 2025262150
MOLÉCULES DE RECRUTEMENT D'ANTICORPS
granted -
AR 133055
DOMINIOS VARIABLES ÚNICOS DE INMUNOGLOBULINA DIRIGIDOS A PD-L1
granted -
MX 2025007399
PROTEIN-BASED CONJUGATION CARRIERS
granted -
WO 2025133166
VÉHICULES À BASE DE PROTÉINES POUR CONJUGAISON D'AMINE SPÉCIFIQUE À UN SITE
granted -
WO 2025133252
DOMAINES VARIABLES UNIQUES D'IMMUNOGLOBULINE CIBLANT CEACAM5
granted -
WO 2025133253
EXCIPIENTS DE CONJUGAISON PROTÉINIQUES POUR ADMINISTRATION INTRANUCLÉAIRE
granted
Frequently asked questions
What is US patent 2024166750?
US 2024166750 (GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION) is held by ABLYNX NV [BE]. Status: granted. Granted May 23, 2024. Expires May 18, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2024166750?
ABLYNX NV [BE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2024166750 expire?
Our index shows an expiration date of May 18, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.